CardioCampus

This webinar will focus on the latest research findings from international experts presented at the AHA 2025. These perspectives can impact profound changes and improvements in their clinical approach.

 Program Learning Objectives:

• To review new data relevant to clinical practice
• To discuss the latest clinical trial data from AHA 2025 and apply it to daily practice

Program Chair and Moderator: Dr. Anil Gupta

Discussants: Dr. Robert Hegele and Dr. George Thanassoulis 

Trial Topics:

• VESALIUS-CV - Effect of Evolocumab in Patients at High Cardiovascular Risk without Prior Myocardial Infarction or Stroke: Primary Results of the VESALIUS-CV trial  
• CORALreef Lipids – Efficacy and Safety of Enlicitide, an Oral PCSK9 Inhibitor, for Lowering LDL Cholesterol in Adults with or At-Risk for ASCVD: The Phase 3 CORALreef Lipids Trial 
• CORALreef HeFH – Enlicitide, an oral PCSK9 inhibitor, in participants with heterozygous familial hypercholesterolemia: a double-blind, Phase 3, randomized placebo-controlled trial